IMpower131 e IMpower150, nuovi dati sul carcinoma polmonare metastatico

IMpower131 e IMpower150, nuovi dati sul carcinoma polmonare metastatico

[Oncoinfo – Istantanee di Oncologia: seguici su http://oncoinfo.it] Dal Congresso annuale ASCO 2018 i dati dagli studi IMpower131 e IMpower150 nel Non Small Cell Metastatic, in particolare il dato di PFS per il primo e di OS per il secondo. Abbiamo chiesto un commento a Francesco Grossi, Responsabile della S.S. Tumori Polmonari dell'Ospedale Policlinico San Martino di Genova.

ภาพตัวอย่างวิดีโอ
IMpower131 e IMpower150, nuovi dati sul carcinoma polmonare metastatico
ภาพตัวอย่างวิดีโอ
ASCO 2018: Important developments in lung cancer from targeted therapies and immunotherapy
ภาพตัวอย่างวิดีโอ
AACR 2018: quali novità per il tumore del polmone NSCLC?
ภาพตัวอย่างวิดีโอ
Ca al polmone metastatico, atezolizumb più chemio efficace anche in prima linea
ภาพตัวอย่างวิดีโอ
Quali novità su pembrolizumab nelle neoplasie genitourinarie?
ภาพตัวอย่างวิดีโอ
Ca al polmone avanzato, pembrolizumab efficace fino a 4 anni sia in prima linea sia dopo
ภาพตัวอย่างวิดีโอ
Immunoterapia e NSCLC, novità dal CheckMate 227
ภาพตัวอย่างวิดีโอ
NSCLC in fase avanzata, sopravvivenza maggiore con l’immunoterapia
ภาพตัวอย่างวิดีโอ
ASCO 2018: studio ALEX, dati di PFS presentati a Chicago
ภาพตัวอย่างวิดีโอ
ESMO 2018: gli highlight sul tumore dello stomaco
ภาพตัวอย่างวิดีโอ
ASCO 2018, cos’è emerso a Chicago sul carcinoma mammario?
ภาพตัวอย่างวิดีโอ
Ipertermia Oncologica
ภาพตัวอย่างวิดีโอ
GI ASCO 2018 Recap :: Feb Webinar